Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and Managing Director of Opthea Limited, to discuss OPT-302 or sozinibercept, the company's novel anti-VEGF-C / VEGF-D treatment for wet AMD and other retinal diseases.

Episode Highlights:

0:06 Introduction

0:37 Background of Dr. Baldwin

9:56 Promising data on OPT-302/sozinibercept

16:39 Making decisions as a clinician, industry leader

22:11 Future of the treatment landscape

28:24 What’s next for Opthea?

32:39 Conclusion

Please direct any podcast-related inquiries to [email protected].